22LAN833: A single-arm, open-arm, multicenter Phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of Bcl-2 inhibitor BGB-11417 in patients with relapsed or refractory mantle cell lymphoma
Principal Investigator
Study Number
STUDY02001833
Summary
This study is a 2 -part study for patients with mantle cell lymphoma (MCL). The purpose of this study is to learn more about the investigational drug BGB-11417. This study aims to determine how much BGB-11417 is safe to take, how the body will process it, any side effects, and how well the drug will work in treating this type of cancer. Participants will be asked to take part in 1 of the 2 parts of this study. Part 1 determine how much of the study drug can be taken with the least number of side-effects and part 2 will use the dose determined in part 1 to learn more about the how well the drug works in treating MCL.
Phase
II
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms